NEW YORK and LONDON, January 4th, 2017
Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, has expanded its clinical and regulatory teams. In December 2016, Dr. Brihad Abhyankar joined as Head of Clinical Development and Justine Lees joined as European Head of Regulatory Affairs. In January 2017, Nigel A.S. Hernandez, PhD, joined as Vice President of Worldwide Regulatory Affairs.
